Amoéba
Develops natural microbiological solutions to manage bacterial and fungal risks.
ALMIB | PA
Overview
Corporate Details
- ISIN(s):
- FR0011051598 (+2 more)
- LEI:
- 9695005QNE7C8Z0LXU64
- Country:
- France
- Address:
- 38 AVENUE DES FRERES MONTGOLFIER, 69680 CHASSIEU
- Website:
- https://amoeba-nature.com/en/
- Sector:
- Manufacturing
- Industry:
- Manufacture of other chemical products
Description
Amoéba is a biotechnology company that develops natural microbiological solutions for managing bacterial and fungal risks. The company's core technology is based on the patented use of the amoeba *Willaertia magna* C2c Maky and its biocidal properties. Its primary focus is on agricultural biocontrol, offering a biofungicide derived from a mechanically lysed amoeba. This product targets plant diseases such as mildews, rusts, and powdery mildew, providing a biological alternative to chemical treatments. Amoéba has also developed applications for its technology in the treatment of bacterial risk in industrial water systems, on surfaces, and for chronic wounds.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-12-18 18:00 |
AXPERA wins the SIVAL d'Or Award: further recognising of the effectiveness of A…
|
English | 385.0 KB | ||
| 2025-12-18 18:00 |
AXPERA décroche le SIVAL d'Or : une nouvelle reconnaissance de l'efficacité de …
|
French | 421.7 KB | ||
| 2025-11-20 18:00 |
Amoéba organise une visioconférence ouverte à tous le lundi 1er décembre 2025 à…
|
French | 346.0 KB | ||
| 2025-11-18 08:00 |
Une innovation naturelle dans la protection des céréales et des cultures de ple…
|
French | 188.3 KB | ||
| 2025-11-18 08:00 |
A natural breakthrough in protecting cereals and field crops // Syngenta and Am…
|
English | 220.7 KB | ||
| 2025-10-29 08:00 |
Amoéba presents the 2025 results of its vineyard trial campaign: AXPERA confirm…
|
English | 425.8 KB | ||
| 2025-10-29 08:00 |
Amoéba présente le bilan 2025 de sa campagne d'essais viticoles : AXPERA confir…
|
French | 424.0 KB | ||
| 2025-10-24 18:00 |
Amoéba: Publication of the half-year financial report as of June 30, 2025
|
English | 319.4 KB | ||
| 2025-10-24 18:00 |
Amoéba : Mise à disposition du rapport financier semestriel au 30 juin 2025
|
French | 314.9 KB | ||
| 2025-10-20 18:30 |
AXPERA named biocontrol solution of the year 2025 // Amoeba's anti-fungal innov…
|
English | 388.0 KB | ||
| 2025-10-20 18:30 |
AXPERA désignée solution de biocontrôle de l'année 2025 // L'innovation anti-ma…
|
French | 414.4 KB | ||
| 2025-10-16 18:00 |
Amoéba obtains market authorisation in the United States for its AXPERA biocont…
|
English | 397.0 KB | ||
| 2025-10-16 18:00 |
Amoéba obtient l'autorisation de mise sur le marché aux États-Unis pour sa solu…
|
French | 373.3 KB | ||
| 2025-10-15 18:00 |
Amoéba announces the appointment of Jean-Marc PETAT as Managing Director of Gre…
|
English | 362.3 KB | ||
| 2025-10-15 18:00 |
Amoéba annonce la nomination de Jean-Marc PETAT en tant que Directeur général d…
|
French | 383.3 KB |
Automate Your Workflow. Get a real-time feed of all Amoéba filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Amoéba
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Amoéba via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-08-30 | N/A | Other | Buy | 6,300 | 3,609.90 EUR |
| 2024-08-29 | N/A | Other | Sell | 5,500 | 3,564.00 EUR |
| 2024-08-28 | N/A | Other | Buy | 3,200 | 1,782.08 EUR |
| 2024-08-27 | N/A | Other | Buy | 20,049 | 11,231.45 EUR |
| 2024-08-26 | N/A | Other | Buy | 31,107 | 17,441.69 EUR |
| 2024-08-22 | N/A | Other | Buy | 2,255 | 1,298.88 EUR |
| 2024-08-20 | N/A | Other | Buy | 16,664 | 8,838.59 EUR |
| 2024-08-19 | N/A | Other | Buy | 13,390 | 6,795.43 EUR |
| 2024-08-16 | N/A | Other | Buy | 6,745 | 3,468.28 EUR |
| 2024-08-09 | N/A | Other | Buy | 40,748 | 21,559.77 EUR |
Peer Companies
